NDC 0078-0883

ADAKVEO

Crizanlizumab

ADAKVEO is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Crizanlizumab.

Product ID0078-0883_b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6
NDC0078-0883
Product TypeHuman Prescription Drug
Proprietary NameADAKVEO
Generic NameCrizanlizumab
Dosage FormInjection
Route of AdministrationINTRAVENOUS
Marketing Start Date2019-11-15
Marketing CategoryBLA / BLA
Application NumberBLA761128
Labeler NameNovartis Pharmaceuticals Corporation
Substance NameCRIZANLIZUMAB
Active Ingredient Strength10 mg/mL
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 0078-0883-61

10 mL in 1 VIAL, GLASS (0078-0883-61)
Marketing Start Date2019-11-15
NDC Exclude FlagN
Sample Package?N

Drug Details

Active Ingredients

IngredientStrength
CRIZANLIZUMAB10 mg/mL

© 2019 FDA.report
This site is not affiliated with or endorsed by the FDA.